Trial Profile
A Phase III Multicenter Clinical Trial of Analatro [Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2] in Patients With Systemic Latrodectism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Antivenin Latrodectus (Primary)
- Indications Spider venom poisoning
- Focus Therapeutic Use
- Acronyms BWS P3
- Sponsors Instituto Bioclon
- 21 Oct 2015 New trial record